139 related articles for article (PubMed ID: 26479144)
81. Cell-based therapy for prevention and reversal of myocardial remodeling.
Karantalis V; Balkan W; Schulman IH; Hatzistergos KE; Hare JM
Am J Physiol Heart Circ Physiol; 2012 Aug; 303(3):H256-70. PubMed ID: 22636682
[TBL] [Abstract][Full Text] [Related]
82. Imaging-Specific Cardiomyopathies: A Practical Guide.
Rankin K; Thampinathan B; Thavendiranathan P
Heart Fail Clin; 2019 Apr; 15(2):275-295. PubMed ID: 30832818
[TBL] [Abstract][Full Text] [Related]
83. Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial.
Lang NN; Ahmad FA; Cleland JG; O'Connor CM; Teerlink JR; Voors AA; Taubel J; Hodes AR; Anwar M; Karra R; Sakata Y; Ishihara S; Senior R; Khemka A; Prasad NG; DeSouza MM; Seiffert D; Ye JY; Kessler PD; Borentain M; Solomon SD; Felker GM; McMurray JJV
Eur J Heart Fail; 2021 Jul; 23(7):1147-1155. PubMed ID: 33620131
[TBL] [Abstract][Full Text] [Related]
84. Orthotopic Heart Transplantation for Ankylosing Spondylitis Masquerading as Nonischemic Cardiomyopathy.
Thakkar SJ; Grayburn PA; Hall SA; Roberts WC
Am J Cardiol; 2019 May; 123(10):1732-1735. PubMed ID: 30898307
[TBL] [Abstract][Full Text] [Related]
85. Emerging role of cardiac computed tomography in heart failure.
Aziz W; Claridge S; Ntalas I; Gould J; de Vecchi A; Razeghi O; Toth D; Mountney P; Preston R; Rinaldi CA; Razavi R; Niederer S; Rajani R
ESC Heart Fail; 2019 Oct; 6(5):909-920. PubMed ID: 31400060
[TBL] [Abstract][Full Text] [Related]
86. Translational development of mesenchymal stem cell therapy for cardiovascular diseases.
Hare JM
Tex Heart Inst J; 2009; 36(2):145-7. PubMed ID: 19436809
[No Abstract] [Full Text] [Related]
87. The value of CMR for determination of heart failure etiology: An unusual case with histology validation.
Cheng S; Wang H; Lu M; Cui C; Li L; Yin G; Zhao S
Int J Cardiol; 2017 Jan; 226():38-41. PubMed ID: 27783967
[No Abstract] [Full Text] [Related]
88. First-in-Human Use of a Retention-Enhanced Catheter for Endomyocardial Cell Delivery.
Sherman W; Bartunek J; Dolatabadi D; Sanz-Ruiz R; Beleslin B; Wojakowski W; Heyndrickx G; Kimpalou JZ; Waldman SA; Laarman GJ; Seron A; Behfar A; Latere JP; Terzic A; Wijns W;
JACC Cardiovasc Interv; 2018 Feb; 11(4):412-414. PubMed ID: 29471956
[No Abstract] [Full Text] [Related]
89. Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study.
Kastrup J; Schou M; Gustafsson I; Nielsen OW; Møgelvang R; Kofoed KF; Kragelund C; Hove JD; Fabricius-Bjerre A; Heitman M; Haack-Sørensen M; Lund LD; Johansen EM; Qayyum AA; Mathiasen AB; Ekblond A
Stem Cells Int; 2017; 2017():8506370. PubMed ID: 29056973
[TBL] [Abstract][Full Text] [Related]
90. It's time to study cardiac magnetic resonance imaging as a strategic tool in nonischemic cardiomyopathy.
Ghosh N; Kwong RY
Circ Heart Fail; 2014 May; 7(3):391-3. PubMed ID: 24847127
[No Abstract] [Full Text] [Related]
91. Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction.
Greene SJ; Vaduganathan M; Gheorghiade M
Eur J Heart Fail; 2017 Jul; 19(7):870-872. PubMed ID: 28464398
[No Abstract] [Full Text] [Related]
92. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.
Bolli R; Solankhi M; Tang XL; Kahlon A
Cardiovasc Res; 2022 Mar; 118(4):951-976. PubMed ID: 33871588
[TBL] [Abstract][Full Text] [Related]
93. Considerations for Clinical Trials Targeting the Myocardial Interstitium.
Lewis GA; Dodd S; Naish JH; Selvanayagam JB; Dweck MR; Miller CA
JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2319-2331. PubMed ID: 31422145
[TBL] [Abstract][Full Text] [Related]
94. Understanding heart failure and cardiomyopathy in Africa: Insights from cardiovascular magnetic resonance.
Ismail TF
Int J Cardiol; 2024 May; 402():131847. PubMed ID: 38354982
[No Abstract] [Full Text] [Related]
95. How do resident stem cells repair the damaged myocardium?
Hayashi E; Hosoda T
World J Stem Cells; 2015 Jan; 7(1):182-5. PubMed ID: 25621118
[TBL] [Abstract][Full Text] [Related]
96. Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model.
Giraldo A; Talavera López J; Fernandez-Del-Palacio MJ; García-Nicolás O; Seva J; Brooks G; Moraleda JM
J Vis Exp; 2018 Jan; (131):. PubMed ID: 29443073
[TBL] [Abstract][Full Text] [Related]
97. Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy?
Traverse JH
Circ Res; 2017 Jan; 120(2):256-258. PubMed ID: 28104762
[No Abstract] [Full Text] [Related]
98. Insights From 10-Year Outcomes of Mesenchymal Stem Cell Transplantation in Heart Failure Patients.
Inoue O; Takamura M
Circ J; 2019 Jun; 83(7):1446-1448. PubMed ID: 31142705
[No Abstract] [Full Text] [Related]
99. Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure.
Poglajen G; Zemljič G; Frljak S; Cerar A; Andročec V; Sever M; Černelč P
Stem Cells Int; 2018; 2018():6487812. PubMed ID: 29535775
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
